Syn-Ake vs Cardiogen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Syn-Ake is a synthetic tripeptide that mimics waglerin-1, a peptide found in the venom of the Temple viper (Tropidolaemus wagleri). It acts as a reversible antagonist of muscular nicotinic acetylcholine receptors, temporarily reducing facial muscle contraction and smoothing dynamic wrinkles. Often called a 'synthetic Botox' in cosmetic marketing.
- Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
- Half-Life
- Not applicable (topical; effect duration hours)
- Short (minutes); gene-regulatory effects persist longer
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.01–0.1% (4–8 mg/g in clinical studies)
- 10 mg per day
- Frequency
- Twice daily
- Daily for 10–30 days
- Key Benefits
- Reduces depth of dynamic wrinkles and expression lines
- Reversible muscle-relaxing effect on facial muscles
- Smooths forehead lines, crow's feet, and frown lines
- Non-invasive alternative to injectable neurotoxins
- Rapid onset relative to collagen-stimulating peptides
- Well-studied in in vitro and clinical cosmetic trials
- Cardioprotective effects on myocardial tissue
- Normalization of cardiomyocyte protein synthesis
- May improve cardiac rhythm and conduction
- Support for recovery from ischemic cardiac events
- Anti-aging effects on heart tissue
- Potential reduction in cardiac fibrosis
- Often combined with Epithalon for comprehensive cardiovascular longevity support
- Side Effects
- Generally very well-tolerated topically
- Rare skin sensitivity or contact dermatitis
- Theoretical neuromuscular effects at systemic doses (not relevant topically)
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse cardiovascular events reported at standard doses
- Stacks With
- —
- —